跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
洪 明賜
臨床教授
,
醫學系
電子郵件
D000008524
cgu.edu
tw
h-index
h10-index
h5-index
1166
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
512
引文
13
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
103
引文
6
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(6)
研究產出
(71)
相近領域學者
(6)
指紋
查看啟用 Ming-Szu Hung 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Lung Cancer
85%
Cancer Cell
37%
Inpatient
34%
Upper Gastrointestinal Bleeding
31%
Non Small Cell Lung Cancer
31%
Epidermal Growth Factor Receptor
23%
Association
22%
Survival
21%
Cullin
20%
Intensive Care Unit
18%
Scoring System
17%
Lung Adenocarcinoma
16%
Diagnosis
16%
Hazard Ratio
15%
Chemosensitivity
15%
Mortality
15%
Therapeutic Procedure
15%
Exon
14%
Gene
14%
Hospital
13%
Development
13%
Screening
13%
Combination Therapy
12%
Real-Time Polymerase Chain Reaction
11%
In Vitro
11%
Tumor Progression
11%
Observational Study
10%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Growth
10%
Mutant
10%
Transgenic Mouse
10%
Malignant Pleural Effusion
10%
Vasculotropin
10%
Incidence
10%
Immunohistochemistry
10%
Age
9%
Tissues
9%
Malignant Neoplasm
9%
Epidermal Growth Factor Receptor
9%
Emergency Department
8%
Overall Survival
8%
Gefitinib
8%
Surgery
8%
Analysis
8%
Cancer Growth
8%
Death
7%
Artificial Respiration
7%
Specimen
7%
Cells
7%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
51%
Mutation
30%
Cullin
27%
Epidermal Growth Factor Receptor
27%
Nested Gene
19%
Development
16%
Survival
16%
Chemosensitivity
15%
Transgenic Mouse
15%
Promoter Region
15%
Mouse Model
14%
Exon
13%
Cell Growth
12%
Growth
12%
Association
10%
Regulatory Mechanism
10%
Demethylation
10%
Protein
9%
Mouse
8%
Mutant
8%
Methylation
7%
Receptor Tyrosine Kinase Inhibitors
7%
Allele
7%
Fusion Gene
6%
Upregulation
6%
Sequencing
6%
DNA
6%
Fluorescence in Situ Hybridization
6%
Comprehension
5%
Oncogene
5%
Tumor Suppressor Protein
5%
Tissue Oxygenation
5%
Vascular Endothelial Growth Factor
5%
Near Infrared Spectroscopy
5%
Lipid Droplet
5%
Dose
5%
Tumor Initiation
5%
Annexin
5%
Gemcitabine
5%
Computer Model
5%
Lipid
5%
Tumor Progression
5%
TaqMan
5%
TGFBI
5%
Casein Kinase
5%
Annexin A1
5%
Cadherin
5%
Gene Amplification
5%
ROS1
5%
Cardiac Arrest
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
51%
Non Small Cell Lung Cancer
30%
Overall Survival
17%
Malignant Neoplasm
17%
Cullin
15%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Survival
13%
Lung Adenocarcinoma
11%
Proton Pump Inhibitor
10%
Natural Product
10%
Death
8%
Cohort Study
7%
Epidermal Growth Factor Receptor
7%
Cancer Growth
6%
Afatinib
6%
Metastasis
6%
Progression Free Survival
6%
Gefitinib
6%
Retrospective Study
5%
Lung Tumor
5%
Chronic Obstructive Lung Disease
5%
Dermatophagoides
5%
Virtual Screening
5%
Paraffin
5%
Formaldehyde
5%
Gemcitabine
5%
Osteoarthropathy
5%
Sensitization
5%
Annexin
5%
Acetylsalicylic Acid
5%
Depression
5%
Transgenic Mouse
5%
STAT3 Protein
5%
Infection
5%
Statin (Protein)
5%
Fatigue
5%
Dimer
5%
Chemoradiation Therapy
5%
Casein Kinase II
5%
Pleura Mesothelioma
5%
Malignant Pleura Effusion
5%
Enolase
5%
Dehydroepiandrosterone Sulfate
5%
Fibrinogen
5%
Factor A
5%
Thromboembolism
5%
